NGS Streamlines Biomarker Testing in Solid Tumors
Next-generation sequencing (NGS) improves biomarker testing and treatment planning in solid tumors, according to Chen, PharmD, MS, BCOP, CPP.
- Experts, including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, discuss the benefits of NGS in oncology.
- Mark Agulnik, MD, and Mrinal M. Zuckerman, MD, also share their insights on NGS in solid tumors.
- Other experts, such as Naval G. Daver, MD, and Jessica Altman, MD, contribute to the discussion on NGS and biomarker testing.
NGS improves biomarker testing and treatment planning in solid tumors.
Experts in the field, including Anne Chiang, MD, PhD, and J. Douglas Miles, MD, PhD, FAAN, highlight the importance of NGS in oncology nursing.
Author's summary: NGS enhances biomarker testing in solid tumors.